Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ImmuCell stock price, quote, forecast and news

ICCC
US4525253062
885825

Price

4.17
Today +/-
+0
Today %
+0 %
P

ImmuCell Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ImmuCell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImmuCell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImmuCell’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ImmuCell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ImmuCell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ImmuCell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImmuCell’s growth potential.

ImmuCell Revenue, EBIT and net profit per share

DateImmuCell RevenueImmuCell EBITImmuCell Net Income
202317.47 M undefined-5.75 M undefined-5.77 M undefined
202218.57 M undefined-2.3 M undefined-2.49 M undefined
202119.24 M undefined260,000 undefined-80,000 undefined
202015.34 M undefined-1.38 M undefined-1.02 M undefined
201913.72 M undefined-950,000 undefined-1.3 M undefined
201810.99 M undefined-2.15 M undefined-2.32 M undefined
201710.43 M undefined-240,000 undefined-170,000 undefined
20169.54 M undefined890,000 undefined510,000 undefined
201510.23 M undefined2.12 M undefined1.21 M undefined
20147.6 M undefined-210,000 undefined-170,000 undefined
20136.01 M undefined-20,000 undefined120,000 undefined
20125.39 M undefined250,000 undefined90,000 undefined
20115.11 M undefined-630,000 undefined-410,000 undefined
20104.39 M undefined-690,000 undefined-380,000 undefined
20094.51 M undefined-530,000 undefined-220,000 undefined
20084.63 M undefined-1.17 M undefined-470,000 undefined
20076.07 M undefined870,000 undefined660,000 undefined
20064.8 M undefined770,000 undefined650,000 undefined
20054.98 M undefined940,000 undefined710,000 undefined
20043.7 M undefined120,000 undefined140,000 undefined

ImmuCell Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0112223344444456633446444556710910101315191817
---100.00--50.00-33.33-----25.0020.00--50.00-33.33-50.00-33.33--25.00-20.0016.6742.86-10.0011.11-30.0015.3826.67-5.26-5.56
----50.00-33.3366.6750.0050.0050.0050.0050.0050.0040.0050.0050.0066.6766.6775.0050.0050.0050.0050.0050.0040.0060.0050.0057.1460.0055.5650.0050.0046.1540.0042.1138.8917.65
00001012222222233223232222334655566873
00-1-10-10000000000000000-1000000200-20-10-2-5
---100.00-50.00--50.00-----------------25.00------20.00---20.00--6.67--11.11-29.41
00-100-100000000200000000000000100-2-1-10-2-5
----------------------------------50.00---150.00
1.071.681.991.991.991.992.112.342.612.292.322.532.432.522.822.842.82.822.9733.053.032.892.962.972.983.113.093.033.044.344.955.496.827.217.597.757.75
--------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ImmuCell Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ImmuCell is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ImmuCell provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ImmuCell's financial health and stability.

Assets

ImmuCell's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ImmuCell must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ImmuCell after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ImmuCell's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-100-100000000200000000000000100-2-1-10-2
00000000000000000000000000000012222
000000000000-10000000000000000000000
0000000000000000000-100000000-100-10-1-1
00000000000000000000000000000000000
00000000000000000000000000000000000
00000000000000000000000000000000000
000-1000000000011101000000102010010-1
0000000000000000-100-1000000-1-2-3-17-2-1-4-2-3
0001,0000000000000-1,0000-3,000-1,000-1,0000000-1,0001,000-1,000-1,000-4,000-4,000-12,000-1,000-3,000-2,000-1,000-3,000
0001000000000000-1-1-110000100-1050-2110
00000000000000000000000000000000000
0000000000000000000000000002050-1101
00000000000000000000000000008308040
00000000000000000000000000028906131
-----------------------------------
00000000000000000000000000000000000
0000000000000000-1000000010-103-1-1303-4
-0.6-0.65-0.71-1.26-0.33-0.28-0.50.22-0.430.040.570.55-0.20.021.651.10.060.581.37-1.18-0.36-0.57-0.93-0.280.060.5-1.240.18-3.91-16.58-2.4-1.16-2.75-1.66-5.52
00000000000000000000000000000000000

ImmuCell stock margins

The ImmuCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmuCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmuCell.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ImmuCell's sales revenue. A higher gross margin percentage indicates that the ImmuCell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ImmuCell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ImmuCell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImmuCell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImmuCell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImmuCell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ImmuCell Margin History

ImmuCell Gross marginImmuCell Profit marginImmuCell EBIT marginImmuCell Profit margin
202322.15 %-32.9 %-33.05 %
202241.2 %-12.39 %-13.41 %
202145.01 %1.35 %-0.42 %
202044.72 %-9 %-6.65 %
201949.13 %-6.92 %-9.48 %
201847.22 %-19.56 %-21.11 %
201750.05 %-2.3 %-1.63 %
201656.81 %9.33 %5.35 %
201561.09 %20.72 %11.83 %
201458.55 %-2.76 %-2.24 %
201350.92 %-0.33 %2 %
201256.59 %4.64 %1.67 %
201154.99 %-12.33 %-8.02 %
201052.39 %-15.72 %-8.66 %
200953.22 %-11.75 %-4.88 %
200844.71 %-25.27 %-10.15 %
200762.6 %14.33 %10.87 %
200660.83 %16.04 %13.54 %
200567.27 %18.88 %14.26 %
200460.81 %3.24 %3.78 %

ImmuCell Stock Sales Revenue, EBIT, Earnings per Share

The ImmuCell earnings per share therefore indicates how much revenue ImmuCell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImmuCell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImmuCell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImmuCell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImmuCell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ImmuCell Revenue, EBIT and net profit per share

DateImmuCell Sales per ShareImmuCell EBIT per shareImmuCell Earnings per Share
20232.26 undefined-0.74 undefined-0.75 undefined
20222.4 undefined-0.3 undefined-0.32 undefined
20212.53 undefined0.03 undefined-0.01 undefined
20202.13 undefined-0.19 undefined-0.14 undefined
20192.01 undefined-0.14 undefined-0.19 undefined
20182 undefined-0.39 undefined-0.42 undefined
20172.11 undefined-0.05 undefined-0.03 undefined
20162.2 undefined0.21 undefined0.12 undefined
20153.37 undefined0.7 undefined0.4 undefined
20142.51 undefined-0.07 undefined-0.06 undefined
20131.94 undefined-0.01 undefined0.04 undefined
20121.73 undefined0.08 undefined0.03 undefined
20111.71 undefined-0.21 undefined-0.14 undefined
20101.48 undefined-0.23 undefined-0.13 undefined
20091.52 undefined-0.18 undefined-0.07 undefined
20081.6 undefined-0.4 undefined-0.16 undefined
20072 undefined0.29 undefined0.22 undefined
20061.57 undefined0.25 undefined0.21 undefined
20051.66 undefined0.31 undefined0.24 undefined
20041.25 undefined0.04 undefined0.05 undefined

ImmuCell business model

ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.com.

ImmuCell SWOT Analysis

Strengths

ImmuCell Corp has several strengths that contribute to its competitive advantage in the market:

  • Strong brand reputation in the animal health industry.
  • Unique and innovative product offerings that address specific customer needs.
  • Extensive research and development capabilities, allowing for continuous improvement and product enhancements.
  • Efficient manufacturing processes that ensure high-quality products and cost-effectiveness.
  • Experienced management team with industry expertise and a track record of success.

Weaknesses

Despite its strengths, ImmuCell Corp also faces certain weaknesses that can hinder its growth and performance:

  • Reliance on a limited number of key customers for a significant portion of its revenue.
  • Vulnerability to pricing pressures due to intense competition in the market.
  • Limited international presence, potentially missing out on global market opportunities.
  • Dependence on a few key suppliers for essential raw materials.
  • Legal and regulatory challenges that may impact product development and approval processes.

Opportunities

ImmuCell Corp can explore several opportunities to further expand its business and improve market positioning:

  • Increasing demand for animal health products, driven by a growing pet population and rising awareness of animal welfare.
  • Expansion into international markets to tap into emerging economies and untapped customer segments.
  • Strategic partnerships or collaborations with complementary companies to diversify product offerings and reach new markets.
  • Ongoing advancements in biotechnology and healthcare, presenting possibilities for developing innovative solutions.
  • Evolving regulatory landscape that may create favorable conditions for product development and marketing.

Threats

ImmuCell Corp should be mindful of the following threats that could impact its business operations and profitability:

  • Intense competition from existing and emerging players in the animal health industry.
  • Fluctuating raw material prices, potentially affecting production costs and profit margins.
  • Changing consumer preferences and market trends that may require constant adaptation and product evolution.
  • Economic downturns or recessions that could lead to reduced customer spending on non-essential products.
  • Stringent regulations and compliance requirements, posing challenges to product development and marketing efforts.

ImmuCell historical P/E ratio, EBIT, and P/S ratio.

ImmuCell shares outstanding

The number of shares was ImmuCell in 2023 — This indicates how many shares 7.748 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImmuCell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImmuCell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImmuCell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImmuCell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ImmuCell Stock splits

In ImmuCell's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for ImmuCell.

ImmuCell latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240 -0.06  (0 %)2024 Q1
12/31/20230 -0.15  (0 %)2023 Q4
9/30/20230 -0.12  (0 %)2023 Q3
6/30/20230 -0.18  (0 %)2023 Q2
3/31/20230 -0.3  (0 %)2023 Q1
12/31/20220 -0.22  (0 %)2022 Q4
12/31/2020-0.04 0.03  (173.53 %)2020 Q4
9/30/2020-0.08 -0.04  (50.98 %)2020 Q3
6/30/2020-0.1 -0.11  (-7.84 %)2020 Q2
1

ImmuCell list of shareholders

%
Name
Stocks
Change
Date
8.25 % Pessin (Norman H)644,01904/15/2024
6.58 % Rothschild (Jonathan E)514,00304/15/2024
5.14 % Pessin (Sandra F)401,81904/15/2024
2.76 % Brigham (Michael F)215,75204/15/2024
2.65 % The Vanguard Group, Inc.206,6061,50912/31/2023
1.83 % Crabb (Joseph H)142,84504/15/2024
1.75 % Pessin (Brian L)136,88204/15/2024
1.62 % Renaissance Technologies LLC126,1894,80912/31/2023
1.33 % Cresset Asset Management, LLC103,606012/31/2023
1.33 % Tomsche (David Scott)103,60604/15/2024
1
2
3
4
5
...
6

ImmuCell Executives and Management Board

Mr. Michael Brigham62
ImmuCell President, Chief Executive Officer, Treasurer, Secretary, Director (since 1991)
Compensation 599,944
Ms. Bobbi Brockmann47
ImmuCell Vice President - Sales and Marketing, Director (since 2015)
Compensation 287,681
Ms. Elizabeth Williams67
ImmuCell Vice President - Manufacturing Operations
Compensation 279,938
Dr. David Tomsche66
ImmuCell Independent Non-Executive Chairman of the Board
Compensation 72,500
Mr. Steven Rosgen57
ImmuCell Independent Director
Compensation 60,500
1
2

ImmuCell Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Patterson Companies Stock
Patterson Companies
SupplierCustomer0,470,060,180,440,340,69
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,45-0,090,230,36-0,300,50
1

Most common questions regarding ImmuCell

What values and corporate philosophy does ImmuCell represent?

ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.

In which countries and regions is ImmuCell primarily present?

ImmuCell Corp is primarily present in the United States.

What significant milestones has the company ImmuCell achieved?

ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.

What is the history and background of the company ImmuCell?

ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.

Who are the main competitors of ImmuCell in the market?

The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.

In which industries is ImmuCell primarily active?

ImmuCell Corp is primarily active in the animal health industry.

What is the business model of ImmuCell?

ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.

What is the P/E ratio of ImmuCell 2024?

The P/E ratio cannot be calculated for ImmuCell at the moment.

What is the P/S ratio of ImmuCell 2024?

The P/S cannot be calculated for ImmuCell currently.

What is the AlleAktien quality score of ImmuCell?

The AlleAktien quality score for ImmuCell is 5/10.

What is the revenue of ImmuCell 2024?

The revenue cannot currently be calculated for ImmuCell.

How high is the profit of ImmuCell 2024?

The profit cannot currently be calculated for ImmuCell.

What is the business model of ImmuCell

ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.

What is the ImmuCell dividend?

ImmuCell pays a dividend of 0 USD distributed over payouts per year.

How often does ImmuCell pay dividends?

The dividend cannot currently be calculated for ImmuCell or the company does not pay out a dividend.

What is the ImmuCell ISIN?

The ISIN of ImmuCell is US4525253062.

What is the ImmuCell WKN?

The WKN of ImmuCell is 885825.

What is the ImmuCell ticker?

The ticker of ImmuCell is ICCC.

How much dividend does ImmuCell pay?

Over the past 12 months, ImmuCell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuCell is expected to pay a dividend of 0 USD.

What is the dividend yield of ImmuCell?

The current dividend yield of ImmuCell is .

When does ImmuCell pay dividends?

ImmuCell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ImmuCell?

ImmuCell paid dividends every year for the past 0 years.

What is the dividend of ImmuCell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ImmuCell located?

ImmuCell is assigned to the 'Health' sector.

Wann musste ich die Aktien von ImmuCell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ImmuCell from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did ImmuCell pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of ImmuCell in the year 2023?

In the year 2023, ImmuCell distributed 0 USD as dividends.

In which currency does ImmuCell pay out the dividend?

The dividends of ImmuCell are distributed in USD.

All fundamentals about ImmuCell

Our stock analysis for ImmuCell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.